{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Head+and+Neck+Carcinoma&page=3", "query": { "condition": "Locally Advanced Head and Neck Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 320, "total_pages": 32, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Head+and+Neck+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Head+and+Neck+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T02:12:10.667Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00268437", "title": "Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2006-04", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 90, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" }, { "city": "Carthage", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00268437" }, { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" }, { "nct_id": "NCT03150810", "title": "Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "Pamiparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2017-06-28", "completion_date": "2023-05-04", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 7, "location_summary": "Grand Rapids, Michigan • St Louis, Missouri • New York, New York + 4 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150810" }, { "nct_id": "NCT01051791", "title": "Phase II Study of RAD001 Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Everolimus 10mg daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Julie E. Bauman, MD, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 13, "start_date": "2010-01", "completion_date": "2016-08-05", "has_results": true, "last_update_posted_date": "2017-12-19", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01051791" }, { "nct_id": "NCT02075112", "title": "Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer of Head and Neck" ], "interventions": [ { "name": "Soy isoflavone", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-11", "completion_date": "2019-09", "has_results": false, "last_update_posted_date": "2019-12-06", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02075112" }, { "nct_id": "NCT04417465", "title": "First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-CLS-579", "type": "DRUG" }, { "name": "PD-1 inhibitor", "type": "DRUG" }, { "name": "VEGFR TKI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2020-06-03", "completion_date": "2025-08-21", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 5, "location_summary": "Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04417465" }, { "nct_id": "NCT03452137", "title": "A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 406, "start_date": "2018-04-03", "completion_date": "2024-03-06", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 12, "location_summary": "Duarte, California • La Jolla, California • Santa Monica, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452137" }, { "nct_id": "NCT04424641", "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumor(s)", "Prostate Cancer", "Esophageal Cancer", "Triple Negative Breast Cancer (TNBC)", "Squamous Cell Carcinoma of Head and Neck (SCCHN)", "Non-small Cell Lung Cancer (NSCLC)", "Bladder Cancer", "Uterine Cancer" ], "interventions": [ { "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-07-15", "completion_date": "2021-10-29", "has_results": true, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04424641" }, { "nct_id": "NCT04196283", "title": "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-368", "type": "DRUG" }, { "name": "Tilsotolimod", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-01-22", "completion_date": "2022-10-27", "has_results": false, "last_update_posted_date": "2023-02-27", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 8, "location_summary": "Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04196283" }, { "nct_id": "NCT00005599", "title": "Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-02", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-07T02:12:10.667Z", "location_count": 2, "location_summary": "New York, New York • The Bronx, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005599" } ] }